De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Protagonist Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

De omzet en winst van Protagonist Therapeutics zullen naar verwachting dalen met respectievelijk 7.8% en 34.9% per jaar. De winst per aandeel zal naar verwachting afnemen met 34.7% per jaar. Het rendement op het eigen vermogen zal naar verwachting 1.9% in 3 jaar.

Belangrijke informatie

-34.9%

Groei van de winst

-34.7%

Groei van de winst per aandeel

Biotechs winstgroei	28.6%
Inkomstengroei	-7.8%
Toekomstig rendement op eigen vermogen	1.9%
Dekking van analisten	Good
Laatst bijgewerkt	24 Sep 2024

Recente toekomstige groei-updates

Recent updates

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Apr 13

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Feb 25

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Dec 28

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Jul 04

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 20

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Feb 06

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Jun 15

Protagonist: Too Many Red Flags

Jun 08

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

May 11

Protagonist Is Still Being Undervalued Like There's Real Risk

Feb 01

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Jan 04

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Aug 06

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Jun 19

Protagonist Therapeutics closes $132M capital raise

Jun 18

Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy

Jun 03

This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

May 21

Protagonist EPS beats by $0.03, beats on revenue

May 04

Winst- en omzetgroeiprognoses

NasdaqGM:PTGX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	167	-31	12	94	7
12/31/2025	167	-5	-80	-72	8
12/31/2024	294	131	179	244	8
6/30/2024	319	170	231	232	N/A
3/31/2024	315	162	-64	-63	N/A
12/31/2023	60	-79	-71	-70	N/A
9/30/2023	N/A	-140	-119	-119	N/A
6/30/2023	N/A	-138	-118	-117	N/A
3/31/2023	1	-140	-105	-105	N/A
12/31/2022	27	-127	-109	-108	N/A
9/30/2022	35	-130	-104	-103	N/A
6/30/2022	45	-133	-108	-107	N/A
3/31/2022	47	-122	-118	-117	N/A
12/31/2021	27	-126	-109	-108	N/A
9/30/2021	24	-108	-101	-100	N/A
6/30/2021	27	-81	-88	-88	N/A
3/31/2021	31	-70	-86	-85	N/A
12/31/2020	29	-66	-73	-72	N/A
9/30/2020	26	-65	-68	-68	N/A
6/30/2020	17	-73	-66	-66	N/A
3/31/2020	2	-83	-42	-41	N/A
12/31/2019	0	-77	-42	-42	N/A
9/30/2019	0	-74	-38	-37	N/A
6/30/2019	2	-66	-34	-32	N/A
3/31/2019	22	-45	-52	-51	N/A
12/31/2018	31	-39	-50	-50	N/A
9/30/2018	40	-28	-54	-54	N/A
6/30/2018	43	-24	-5	-4	N/A
3/31/2018	31	-31	N/A	-1	N/A
12/31/2017	20	-37	N/A	4	N/A
9/30/2017	9	-45	N/A	8	N/A
6/30/2017	N/A	-48	N/A	-39	N/A
3/31/2017	N/A	-40	N/A	-35	N/A
12/31/2016	N/A	-38	N/A	-30	N/A
9/30/2016	N/A	-32	N/A	-25	N/A
6/30/2016	N/A	-28	N/A	-22	N/A
3/31/2016	N/A	-24	N/A	-17	N/A
12/31/2015	N/A	-15	N/A	-14	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De winst van PTGX zal naar verwachting de komende 3 jaar dalen ( -34.9% per jaar).

Winst versus markt: De winst van PTGX zal naar verwachting de komende 3 jaar dalen ( -34.9% per jaar).

Hoge groeiwinsten: De winst van PTGX zal naar verwachting de komende 3 jaar dalen.

Omzet versus markt: De omzet van PTGX zal naar verwachting de komende 3 jaar dalen ( -7.8% per jaar).

Hoge groei-inkomsten: De omzet van PTGX zal naar verwachting de komende 3 jaar dalen ( -7.8% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen PTGX zal naar verwachting over 3 jaar laag zijn ( 1.9 %).

Protagonist Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 7.1% to US$43.00

Forecast to breakeven in 2024

Consensus revenue estimates fall by 25%

Price target increased by 10% to US$42.50

Consensus revenue estimates increase by 35%

Price target decreased by 9.1% to US$35.83

Recent updates

Protagonist Therapeutics, Inc. Announces Publication of Phase 1 Clinical Data on JNJ-2113 in the Journal

Protagonist Therapeutics Appoints Newman Yeilding as Chief Scientific Advisor, Effective August 1, 2024

Protagonist Therapeutics, Inc. Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showowing Durable Hematocrit Control

Investor sentiment improves as stock rises 16%

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

CEO, President notifies of intention to sell stock

Executive VP & Chief Financial Officer recently sold US$378k worth of stock

Executive VP & Chief Financial Officer notifies of intention to sell stock

Price target increased by 7.1% to US$43.00

Forecast to breakeven in 2024

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Consensus revenue estimates fall by 25%

Price target increased by 10% to US$42.50

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

CEO, President notifies of intention to sell stock

Protagonist Therapeutics, Inc. Announces $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis

Protagonist Therapeutics, Inc. Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-To-Head Comparisons with Deucravacitinib

Protagonist Therapeutics, Inc. Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-To-Head Comparisons with Deucravacitinib

Consensus revenue estimates increase by 35%

Price target decreased by 9.1% to US$35.83

Consensus revenue estimates increase by 102%

Protagonist Therapeutics, Inc. Announces Achievement of $50 Million Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis

Protagonist Therapeutics, Inc. Announces Appointment of Daniel N. Swisher, Jr. to Its Board of Director

Chief Development Officer exercised options to buy US$282k worth of stock.

Consensus revenue estimates increase by 250%

New minor risk - Profitability

Consensus revenue estimates fall by 30%

Protagonist Therapeutics, Inc. Announces Retirement of Sarah Noonberg as Director

Price target increased by 7.3% to US$39.00

Protagonist Therapeutics, Inc., Annual General Meeting, May 27, 2024

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Price target increased by 9.1% to US$37.83

Consensus revenue estimates increase by 100%

Protagonist Reports Positive Results from Phase 1 and Pre-Clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113

Consensus revenue estimates decrease by 17%, EPS upgraded

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.43 loss in 1Q 2022)

Consensus revenue estimates fall by 51%

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Full year 2022 earnings: EPS and revenues miss analyst expectations

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor

Insider exercised options to buy US$812k worth of stock.

Insufficient new directors

Third quarter 2022 earnings released: US$0.64 loss per share (vs US$0.70 loss in 3Q 2021)

Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer

Price target decreased to US$34.40

CEO, President exercised options to buy US$187k worth of stock.

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Protagonist: Too Many Red Flags

Protagonist Therapeutics, Inc. to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022

Consensus revenue estimates increase by 28%

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Price target decreased to US$48.29

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$52.00

Insufficient new directors

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis

CEO, President exercised options to buy US$680k worth of stock.

Protagonist Therapeutics, Inc., Annual General Meeting, May 26, 2022

Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer

Consensus forecasts updated

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Protagonist Is Still Being Undervalued Like There's Real Risk

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data

Third quarter 2021 earnings released: US$0.70 loss per share (vs US$0.21 loss in 3Q 2020)

CEO, President exercised options to buy US$720k worth of stock.